CClinicalTrials.gg
Status unknownNCT00522704Updated Nov 6, 2014

Correlation Between Access Blood Flow and Extracorporeal Blood Flow

An observational study in Arteriovenous Fistula, sponsored by Instituto Nacional de Cardiologia Ignacio Chavez. Status unknown at 1 site in Mexico. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-11-06.

Sponsored by Instituto Nacional de Cardiologia Ignacio Chavez · Observational

The sponsor has not verified this record recently (last verified Nov 2014), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to determine if Effective Extracorporeal Blood Flow(eEBF) has correlation with Access Blood Flow (Qa), when eEBF adjusts with Dynamic Arterial Line Pressure (DALP) in patients with Arteriovenous fistulae in hemodialysis treatment.

Read the detailed description

Accesses that show a large (>15%) decrement over time in vascular access blood flow are associated with a high risk of thrombosis. Serial measurements of vascular access blood flow predict access thrombosis. At the moment, the measurement of access flow is time consuming, operator dependent, so that it cannot be done with every treatment. We hypothesized that extracorporeal blood flow at pressure of -200 to -260 mmHg in arterial line has correlation with access blood flow and this can be used to estimate access blood flow.

02

Conditions studied

  • Arteriovenous Fistula

Keywords

  • Arteriovenous fistula
  • Access blood flow
  • Extracorporeal blood flow
  • Dynamic arterial line pressure
  • Hemodialysis treatment
03

In context

Arteriovenous Fistula

267 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

This study's planned enrollment of 30 is below the median of 100 across 80 observational studies indexed under Arteriovenous Fistula.

Browse Arteriovenous Fistula studies →

Lead sponsor

Instituto Nacional de Cardiologia Ignacio Chavez is the lead sponsor of 45 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Chronic Kidney Dissease K-DIGO 5d in hemodialysis.

Inclusion criteria

  • Patients with Chronic Kidney Disease K-DIGO 5d in hemodialysis treatment)
  • Permanent vascular accesses with native arteriovenous fistulas (AVF)
  • AVF that were at least 12 weeks old

Exclusion criteria

Exclusion Criteria:

  • Inflammation and pain in AVF
  • Negation to participate in the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)

Interventions

  • OtherDynamic Arterial line Pressure (DALP)

    eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.

    Also known as: BTM,

06

What researchers measure

Primary outcomes

  1. Acces Blood Flow

    Acces Blood Flow: cuantity of Blood that Flow throw venous acces in ml/min

    Time frame: Acces Blood Flow

07

Study locations

1 of 1 sites recruiting
  • Instituto Nacional De Cardiología Ignacio Chávez
    Mexico City, Distrito Federeal 14080, Mexico
    • Luis R Mariscal, M.D. · Contact · mariscalmd@yahoo.com.mx · 52 55 557932911
    • Franklin B Mora, M.D. · Principal investigator
    • Luis R Mariscal, M.D. · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00522704
Lead sponsor
Instituto Nacional de Cardiologia Ignacio Chavez
Collaborators
JOSE CARRASCO ARTEAGA HOSPITAL FROM Ecuadorian Institute of Social Security
Responsible party
FRANKLIN MORA (Doctor, Instituto Nacional de Cardiologia Ignacio Chavez) — Principal investigator
First posted
Aug 30, 2007
Start date
Mar 2008
Primary completion
Apr 2015 (estimated)
Completion
Jun 2015 (estimated)
Last update
Nov 6, 2014

Study contacts

Franklin B Mora, M.D.
Contact
franklin.mora.bravo@gmail.com
593 72 868084
Luis R Mariscal, M.D.
Contact
mariscalmd@yahoo.com.mx
52 55 55 7932911 ext. 1262
Franklin B Mora, M.D.
principal investigator · HOSPITAL JOSE CARRASCO ARTEAGA DEL INSTITUTO ECUATORIANO DE SEGURIDAD SOCIAL REGIONAL 3
Luis R Mariscal, M.D.
study chair · Instituto Nacional de Cardiología Ignacio Chávez
Guadalupe C De la Cruz, R.N.
study chair · Instituto Nacional de Cardiología Ignacio Chávez
Héctor G Pérez-Grovas, M.D.
study chair · Instituto Nacional de Cardiología Ignacio Chávez
Fabián H Ortiz, MsC
principal investigator · Hospital Clínica Kennedy, Guayaquil Ecuador

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion